Literature DB >> 3129812

Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis.

P Hasselaar1, R H Derksen, L Blokzijl, P G de Groot.   

Abstract

The effect of 23 antiphospholipid antibody positive SLE sera, 4 antiphospholipid antibody negative SLE sera and 17 control sera on endothelial prostacyclin and platelet thromboxane A2 production was studied. Endothelial cells and platelets were stimulated with different agonists. Depending on the stimulus used, 4-19% of the SLE sera inhibited the prostacyclin release, whereas 4-28% enhanced prostacyclin production. Our data suggest that the pathophysiological mechanisms underlying decreased prostacyclin production are heterogeneous. Follow-up of two patients showed that prostacyclin inhibitory activity was variable in time. Platelet thromboxane production was normal or increased, but never decreased in the presence of the SLE sera. An imbalance in thromboxane A2/prostacyclin ratio was present in some patients, but did not correlate with a history of thrombosis. We conclude that, in general, interference of antiphospholipid antibodies with endothelial or platelet prostanoid synthesis does not explain the occurrence of thromboembolic manifestations in antiphospholipid antibody positive SLE patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129812

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Anticardiolipin antibody levels in diabetic subjects with and without coronary artery disease.

Authors:  T J Hendra; E Baguley; E N Harris; M H Khamashta; R C Trembath; G R Hughes; J S Yudkin
Journal:  Postgrad Med J       Date:  1989-03       Impact factor: 2.401

Review 2.  The antiphospholipid antibody dilemma.

Authors:  R H Derksen; P Hasselaar; J D Oosting; P G De Groot
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

Review 3.  Antiphospholipid antibodies and the antiphospholipid syndrome.

Authors:  E N Harris; S S Pierangeli
Journal:  Springer Semin Immunopathol       Date:  1994

Review 4.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

5.  Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant.

Authors:  T Mayumi; K Nagasawa; T Inoguchi; Y Yamauchi; Y Ishii; Y Tada; F Umeda; Y Niho
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

6.  Lupus anticoagulant antibodies inhibit collagen-induced adhesion and aggregation of human platelets in vitro.

Authors:  I Ostfeld; N Dadosh-Goffer; S Borokowski; J Talmon; A Mani; U Zor; J Lahav
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

Review 7.  Diagnosis and pathogenesis of CNS lupus.

Authors:  A P van Dam
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.